# A Phase 1/2 Study to Evaluate Axatilimab in Participants With Active cGVHD

> **NCT03604692** · PHASE1,PHASE2 · COMPLETED · sponsor: **Syndax Pharmaceuticals** · enrollment: 41 (actual)

## Conditions studied

- Chronic Graft-versus-host-disease

## Interventions

- **DRUG:** axatilimab

## Key facts

- **NCT ID:** NCT03604692
- **Lead sponsor:** Syndax Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-01
- **Primary completion:** 2022-08-12
- **Final completion:** 2024-10-18
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2025-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03604692

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03604692, "A Phase 1/2 Study to Evaluate Axatilimab in Participants With Active cGVHD". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03604692. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*